Max Yan

2.9k total citations · 1 hit paper
12 papers, 1.4k citations indexed

About

Max Yan is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Max Yan has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Max Yan's work include Genomics and Chromatin Dynamics (3 papers), DNA Repair Mechanisms (2 papers) and Breast Cancer Treatment Studies (2 papers). Max Yan is often cited by papers focused on Genomics and Chromatin Dynamics (3 papers), DNA Repair Mechanisms (2 papers) and Breast Cancer Treatment Studies (2 papers). Max Yan collaborates with scholars based in Australia, United Kingdom and United States. Max Yan's co-authors include Stephen B. Fox, David Gyorki, Heather Thorne, Adam H. Hart, Melissa A. Brown, Natasha C. Forrest, Elgene Lim, Teresa Ward, Frank Feleppa and Geoffrey J. Lindeman and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Breast Cancer Research and Treatment.

In The Last Decade

Max Yan

11 papers receiving 1.4k citations

Hit Papers

Aberrant luminal progenitors as the candidate target popu... 2009 2026 2014 2020 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
    2009 1.0k citations Elgene Lim, François Vaillant et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Yan Australia 7 917 818 472 270 160 12 1.4k
Ina Klebba United States 12 814 0.9× 745 0.9× 311 0.7× 191 0.7× 256 1.6× 19 1.4k
Stephan Duss Switzerland 12 682 0.7× 669 0.8× 520 1.1× 226 0.8× 81 0.5× 13 1.3k
Anne‐Lise Børresen‐Dale Norway 15 446 0.5× 822 1.0× 527 1.1× 210 0.8× 98 0.6× 20 1.2k
Teresa Ward New Zealand 13 974 1.1× 1.2k 1.5× 503 1.1× 308 1.1× 115 0.7× 15 1.8k
Tien-Chi Pan United States 14 618 0.7× 769 0.9× 320 0.7× 118 0.4× 104 0.7× 18 1.2k
Jillian Howlin Sweden 14 471 0.5× 732 0.9× 469 1.0× 140 0.5× 91 0.6× 20 1.2k
Mutsuko Yamamoto‐Ibusuki Japan 20 445 0.5× 553 0.7× 509 1.1× 158 0.6× 183 1.1× 45 1.1k
Eva Schut Netherlands 13 707 0.8× 879 1.1× 228 0.5× 269 1.0× 201 1.3× 15 1.3k
Paul M. Moseley United Kingdom 22 616 0.7× 796 1.0× 314 0.7× 111 0.4× 88 0.6× 45 1.1k
Christopher J. Sarkisian United States 6 719 0.8× 920 1.1× 238 0.5× 175 0.6× 102 0.6× 6 1.3k

Countries citing papers authored by Max Yan

Since Specialization
Citations

This map shows the geographic impact of Max Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Yan more than expected).

Fields of papers citing papers by Max Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Yan. The network helps show where Max Yan may publish in the future.

Co-authorship network of co-authors of Max Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Max Yan. A scholar is included among the top collaborators of Max Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Yan. Max Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Takano, Elena A., Katie Meehan, Max Yan, et al.. (2023). Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival. BMC Cancer. 23(1). 459–459. 4 indexed citations
2.
Wong, Daniel, et al.. (2022). NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern. SHILAP Revista de lepidopterología. 28. 300618–300618. 1 indexed citations
3.
4.
Yan, Max, Kristy Shield‐Artin, David J. Byrne, et al.. (2015). Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. BMC Cancer. 15(1). 506–506. 12 indexed citations
5.
Ye, Xuan, et al.. (2014). A contrast-enhancing lumbar ligamentum flavum haematoma. BMJ Case Reports. 2014. bcr2013202521–bcr2013202521. 6 indexed citations
6.
Yan, Max, Huiling Xu, Nicola Waddell, et al.. (2012). Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Research. 14(2). R69–R69. 35 indexed citations
7.
Yan, Max, Nicholas Jene, David J. Byrne, et al.. (2011). Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research. 13(2). R47–R47. 150 indexed citations
8.
Xu, Huiling, Max Yan, Rachael Natrajan, et al.. (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research. 13(1). R9–R9. 80 indexed citations
9.
Yan, Max, et al.. (2010). Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Research and Treatment. 126(2). 395–405. 48 indexed citations
10.
Dobrovic, Alexander, Max Yan, Rooshdiya Z. Karim, et al.. (2010). DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Research and Treatment. 124(2). 555–565. 30 indexed citations
11.
Lim, Elgene, François Vaillant, Di Wu, et al.. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine. 15(8). 907–913. 1048 indexed citations breakdown →
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ina Klebba Breakdown of academic impact, for papers by Stephan Duss Breakdown of academic impact, for papers by Anne‐Lise Børresen‐Dale Breakdown of academic impact, for papers by Teresa Ward Breakdown of academic impact, for papers by Tien-Chi Pan Breakdown of academic impact, for papers by Jillian Howlin Breakdown of academic impact, for papers by Mutsuko Yamamoto‐Ibusuki Breakdown of academic impact, for papers by Eva Schut Breakdown of academic impact, for papers by Paul M. Moseley Breakdown of academic impact, for papers by Christopher J. Sarkisian
Rankless by CCL
2026